Comparative Pharmacology
Head-to-head clinical analysis: EMEND versus VONTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMEND versus VONTROL.
EMEND vs VONTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective substance P/neurokinin 1 (NK1) receptor antagonist, which inhibits the binding of substance P in the emetic pathway.
VONTROL (trimethobenzamide) acts centrally to inhibit the chemoreceptor trigger zone (CTZ) in the medulla oblongata, thereby suppressing nausea and vomiting. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and serotonin 5-HT3 receptors.
125 mg orally once 1 hour before chemotherapy; then 80 mg orally once daily on Days 2 and 3.
10 mg orally twice daily; maximum 20 mg/day.
None Documented
None Documented
9–13 hours (terminal) in healthy adults; clinically, this supports once-daily dosing. In patients with severe renal impairment (CrCl <30 mL/min), half-life is prolonged to ~16 hours.
12 hours; prolonged in renal impairment (up to 24 hours in ESRD)
Primarily metabolized; ~5% unchanged in urine, ~57% in feces as metabolites, ~32% in urine as metabolites. Renal elimination of parent drug is minimal.
Renal: 60% unchanged; fecal: 30% (biliary); hepatic metabolism: 10%
Category C
Category C
Antiemetic
Antiemetic